PROREGEN

ProRegen is an Australian biotechnology company focused on developing regenerative therapies for cardiovascular diseases. The company was founded to commercialize breakthrough research from the Victor Chang Cardiac Research Institute, specifically targeting the regeneration of heart muscle cells. Their approach utilizes small molecule inhibitors to stimulate the proliferation of cardiomyocytes, which are typically non-dividing in adults. By promoting the growth of new heart tissue, ProRegen aims to treat patients suffering from heart failure and the aftermath of myocardial infarction. The company is backed by leading venture capital firms and is currently progressing its lead candidates through pre-clinical development. Their work represents a potential paradigm shift from managing heart disease symptoms to actively repairing damaged cardiac tissue.